The Anti-Mycobacterial Activity Of Ag, ZnO, And Ag- ZnO Nanoparticles Against MDR- And XDR-Mycobacterium tuberculosis

Mohsen Heidary,1,2 Saeed Zaker Bostanabad,3,4 Seyed Mohammad Amini,5 Alireza Jafari,6 Mostafa Ghalami Nobar,4,7 Arash Ghodousi,8 Morteza Kamalzadeh,9 Davood Darban-Sarokhalil1 1Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran; 2Student Research Commit...

Full description

Bibliographic Details
Published in:	Infection and Drug Resistance
Main Authors:	Heidary M, Zaker Bostanabad S, Amini SM, Jafari A, Ghalami Nobar M, Ghodousi A, Kamalzadeh M, Darban-Sarokhalil D
Format:	Article
Language:	English
Published:	Dove Medical Press 2019-11-01
Subjects:	mycobacterium tuberculosis silver zinc oxide nanoparticle mdr-tb xdr-tb
Online Access:	https://www.dovepress.com/the-anti-mycobacterial-activity-of-ag-zno-and-ag--zno-nanoparticles-ag-peer-reviewed-article-IDR

Similar Items

Impacts of MDR/XDR-TB on the global tuberculosis epidemic: Challenges and opportunities
by: Kai Ling Chin, et al.
Published: (2024-01-01)

Prevalence of Pre-Extensively Drug-Resistant Tuberculosis (Pre XDR-TB) and Extensively Drug-Resistant Tuberculosis (XDR-TB) among Pulmonary Multidrug Resistant Tuberculosis (MDR-TB) at a Tertiary Care Center in Mumbai
by: Unnati D. Desai, et al.
Published: (2016-07-01)

Genotypic and Phenotypic Methods in the Detection of MDR-TB and Evolution to XDR-TB
by: Natalia Zaporojan, et al.
Published: (2025-07-01)

Delamanid in the Treatment of MDR/pre-XDR TB in Arkhangelsk Region in 2019–2021
by: E. S. Khimova, et al.
Published: (2023-07-01)

Linezolid-Associated Neuropathy in Patients with MDR/XDR Tuberculosis in Shenzhen, China
by: Zhang P, et al.
Published: (2022-05-01)

Genomic characterization of MDR/XDR-TB in Kazakhstan by a combination of high-throughput methods predominantly shows the ongoing transmission of L2/Beijing 94–32 central Asian/Russian clusters
by: B. J. Klotoe, et al.
Published: (2019-06-01)

Safety of chemotherapy of MDR/XDR-TB patients in high HIV prevalence settings
by: A. V. Kukurika, et al.
Published: (2022-12-01)

Tuberculosis extremadamente resistente (TB-XDR), historia y situación actual
by: Alberto Mendoza Ticona, et al.
Published: (2018-06-01)

Global burden of MDR-TB and XDR-TB: trends, inequities, and future implications for public health planning
by: En-Li Tan, et al.
Published: (2025-10-01)

XDR TB in South Africa - What lies ahead?
by: V. Thaver, et al.
Published: (2007-12-01)

Pre-XDR spinal tuberculosis and 360° approach in two surgical times: a case report
by: C. Montero-Silva, et al.
Published: (2023-01-01)

Treatment outcomes of extensively drug-resistant tuberculosis in Europe: a retrospective cohort studyResearch in context
by: Yousra Kherabi, et al.
Published: (2025-09-01)

High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region
by: Viola Dreyer, et al.
Published: (2022-08-01)

Pretomanid for tuberculosis treatment: an update for clinical purposes
by: Sara Occhineri, et al.
Published: (2022-01-01)

Frequency of first and second-line drug resistance-associated mutations among resistant Mycobacterium tuberculosis clinical isolates from São Paulo, Brazil
by: Tania Matsui, et al.
Published: (2020-05-01)

Clinical Features and Outcome of Multidrug-Resistant Osteoarticular Tuberculosis: A 12-Year Case Series from France
by: Isabelle Bonnet, et al.
Published: (2022-06-01)

Drug-resistant tuberculosis: an experience from Qatar
by: Maisa Ali, et al.
Published: (2020-01-01)

New drugs and perspectives for new anti-tuberculosis regimens☆
by: S. Tiberi, et al.
Published: (2018-03-01)

Diagnostic accuracy of the Xpert® MTB/XDR assay for detection of Isoniazid and second-line antituberculosis drugs resistance at central TB reference laboratory in Tanzania
by: Togolani Maya, et al.
Published: (2024-07-01)

TB financing in East Europe promotes unnecessary hospital admissions: the case of Armenia
by: Laura Gillini, et al.
Published: (2013-03-01)

Issues of Tuberculosis Drug-Resistance in Kharkiv Region and in Ukraine
by: O.S. Shevchenko, et al.
Published: (2019-11-01)

Knowledge About Tuberculosis and Multi-Drug Resistant Tuberculosis Among Interns
by: Rupali A Patel, et al.
Published: (2014-03-01)

Predominance of Beijing lineage among pre-extensively drug-resistant and extensively drug-resistant strains of Mycobacterium tuberculosis: A tertiary care center experience
by: Syed Beenish Rufai, et al.
Published: (2016-01-01)

On the onset and dispersal of a major MDR TB clone among HIV-negative patients, Tunisia
by: Naira Dekhil, et al.
Published: (2024-02-01)

Exploring health care providers’ engagement in prevention and management of multidrug resistant Tuberculosis and its factors in Hadiya Zone health care facilities: qualitative study
by: Bereket Aberham Lajore, et al.
Published: (2024-04-01)

Performance of the low-cost phenotypic thin-layer agar MDR/XDR-TB Colour Test (first generation, 1G, Color Plate Test) for identifying drug-resistant Mycobacterium tuberculosis isolates in a resource-limited setting
by: Binyam Mebrat, et al.
Published: (2025-10-01)

Analysis of drug resistance among difficult-to-treat tuberculosis patients in Ghana identifies several pre-XDR TB cases
by: Isaac Darko Otchere, et al.
Published: (2023-01-01)

Tailored treatment for tuberculosis in transgender individuals: a call for a patient-centered approach from a large Italian cohort
by: Niccolò Riccardi, et al.
Published: (2024-01-01)

Multidrug-Resistant Tuberculosis In A Referral Center In Rome: 2011– 2016
by: Cannas A, et al.
Published: (2019-10-01)

Updated treatment guidelines for drug-resistant TB: how safe are clofazimine-based regimens?
by: E. Pontali, et al.
Published: (2024-11-01)

Newer research transforming 24-month treatment of MDR/XDR-TB TO 6 months
by: Nitin Jain, et al.
Published: (2025-03-01)

Tackling Drug-Resistant Tuberculosis: New Challenges from the Old Pathogen <i>Mycobacterium tuberculosis</i>
by: Giuseppe Mancuso, et al.
Published: (2023-09-01)

THE ROLE OF THE IMPLANTABLE PORT SYSTEM FOR THE CENTRAL VENOUS ACCESS IN TREATMENT OF PULMONARY TUBERCULOSIS WITH MULTIPLE AND EXTENSIVELY DRUG RESISTANCE (PRELIMINARY RESULTS)
by: О.R. RAZAKOV, et al.
Published: (2018-08-01)

Impact of Delayed Video-Assisted Thoracoscopic Surgery on Pneumonectomy Outcomes in Patients with Tuberculosis
by: D. B. Giller, et al.
Published: (2025-05-01)

Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy
by: L. Kuksa, et al.
Published: (2025-03-01)

Extensively drug resistant tuberculosis in Mali: a case report
by: Bassirou Diarra, et al.
Published: (2017-11-01)

XDR-TB Transmitted from Mother to 10-Month-Old Infant: Diagnostic and Therapeutic Problems
by: Monika Kozińska, et al.
Published: (2022-02-01)

Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial
by: S. B. Patil, et al.
Published: (2023-11-01)

Drug resistance pattern of M. tuberculosis in category II treatment failure pulmonary tuberculosis patients
by: Fahmida Rahman, et al.
Published: (2013-01-01)

Drug-Resistant Tuberculosis, KwaZulu-Natal, South Africa, 2001–2007
by: Kristina Wallengren, et al.
Published: (2011-10-01)